Advagraf

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

tacrolimus

Available from:

Astellas Pharma Europe BV

ATC code:

L04AD02

INN (International Name):

tacrolimus

Therapeutic group:

Immunosoppressanti

Therapeutic area:

Rifjut ta 'Graft

Therapeutic indications:

Profilassi tar-rifjut tat-trapjanti f'riċevituri ta 'l-alloġib tal-kliewi jew tal-fwied adulti. Kura ta 'rifjut tal-allograft reżistenti għat-trattament ma' prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.

Product summary:

Revision: 26

Authorization status:

Awtorizzat

Authorization date:

2007-04-23

Patient Information leaflet

                                29
TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT TA’ BARRA
PAKKETT ADVAGRAF 0.5 MG KAPSULI IBSIN LI JERЋU L-MEDIĊINA BIL-MOD
1.
ISEM IL-PRODOTT MEDIĊINALI
Advagraf 0.5 mg kapsuli ibsin li jer
ћ
u l-
mediċina bil
-mod
Tacrolimus
2.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I)
Kull kapsula fiha 0.5 mg
ta' tacrolimus (bħala monoidrat)
3.
LISTA TA’ EĊĊIPJENTI
Fih ukoll: lactose u traċċi ta’ soja lecithin. Għal aktar
tagħrif ara l
-
fuljett ta’ tagħrif
.
4.
GĦAMLA FARMAĊEWTIKA U KONTENUT
30 kapsula iebsa
li jerћu l
-
mediċina bil
-mod
30×1
kapsula iebsa li jerћu l
-
mediċina bil
-mod
50
kapsula iebsa li jerћu l
-
mediċina bil
-mod
50×1
kapsula iebsa li jerћu l
-
mediċina bil
-mod
100
kapsula iebsa li jerћu l
-
mediċina bil
-mod
100×1 kapsula iebsa li j
erћu l
-
mediċina bil
-mod
5.
MOD TA’ KIF U MNEJN JINGĦATA
Darba kuljum.
Aqra l-
fuljett ta’ tagħrif qabel l
-
użu.
Użu orali.
6.
TWISSIJA SPEĊJALI LI L-PRODOTT MEDIĊINALI GĦANDU JINŻAMM FEJN MA
JIDHIRX U MA JINTLAĦAQX MIT-TFAL
Żomm fejn ma jidhirx u ma jintlaħaqx mit
-tfal.
7.
TWISSIJA(IET) SPEĊJALI OĦRA, JEKK MEĦTIEĠA
Tiblax id-desikkant
8.
DATA TA’ SKADENZA
EXP:
Uża l
-
kapsuli kollha fi żmien sena minn mindu tneħħi l
-qartas tal-aluminju u qabel ma jiskadi.
30
9.
KONDIZZJONIJIET SPEĊJALI TA’ KIF JINĦAŻEN
Aħż
en fil-
pakkett oriġinali sabiex tilqa’ mill
-umdità.
10.
PREKAWZJONIJIET SPEĊJALI GĦAR-RIMI TA’ PRODOTTI MEDIĊINALI MHUX
UŻATI JEW SKART MINN DAWN IL-PRODOTTI MEDIĊINALI, JEKK HEMM
BŻONN
11.
ISEM U INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID
FIS-SUQ
Astellas Pharma Europe B.V.
Sylviusweg 62
2333 BE Leiden
L-Olanda
12.
NUMRU(I) TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ
EU/1/07/387/001 30 kapsula
EU/1/07/387/002 50 kapsula
EU/1/07/387/009 100 kapsula
EU/1/07/387/014 30×1 kapsula
EU/1/07/387/015 50×1 kapsula
EU/1/07/387/016 100×1 kapsula
13.
NUMRU TAL-LOTT
Lott:
14.
KLASSIFIKAZZJONI ĠENERALI TA’ KIF JINGĦATA
Prodott mediċinali li jingħata bir
-
riċetta tat
-tabib.
15.

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Advagraf 0.5 mg kapsuli ibsin
li jerћu l
-
mediċina bil
-mod
Advagraf 1 mg kapsuli ibsin
li jerћu l
-
mediċina bil
-mod
Advagraf 3 mg kapsuli ibsin
li jerћu l
-
mediċina bil
-mod
Advagraf 5 mg kapsuli
ibsin li jerћu l
-
mediċina bil
-mod
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Advagraf 0.5
mg kapsuli ibsin li jerћu l
-
mediċina bil
-mod
Kull kapsula iebsa li terћi l
-
mediċina bil
-mod fiha 0.5 mg
tacrolimus (bћala monoidrat).
Eċċipjenti b’effett magħruf
: Kull kapsula fiha 51.09 mg lactose.
Il-
linka użata gћall
-istampar fuq il-
kapsula fiha traċċi ta’ soja lecithin (0.48% tal
-
kompożizzjoni kollha tal
-
linka gћall
-istampar).
Advagraf 1 mg kapsuli ibs
in li jerћu l
-
mediċina bil
-mod
Kull kapsula iebsa li terћi l
-
mediċina bil
-
mod fiha 1 mg tacrolimus (bћala monoidrat).
Eċċipjenti b’effett magħruf
: Kull kapsula fiha 102.17 mg lactose.
Il-
linka użata gћall
-istampar fuq il-
kapsula fiha traċċi ta’ soja leci
thin (0.48% tal-
kompożizzjoni kollha tal
-
linka gћall
-istampar).
Advagraf 3
mg kapsuli ibsin li jerћu l
-
mediċina bil
-mod
Kull kapsula iebsa li terћi l
-
mediċina bil
-
mod fiha 3 mg tacrolimus (bћala monoidrat).
Eċċipjenti
b’effett magħruf
: Kull kapsula fiha 306.52 mg lactose.
Il-
linka użata gћall
-istampar fuq il-
kapsula fiha traċċi ta’ soja lecithin (0.48% tal
-
kompożizzjoni kollha tal
-
linka gћall
-istampar).
Advagraf 5
mg kapsuli ibsin li jerћu l
-
mediċina bil
-mod
Kull kapsula iebsa li terћi l
-med
iċina bil
-
mod fiha 5 mg tacrolimus (bћala monoidrat).
Eċċipjenti b’effett magħruf
: Kull kapsula fiha 510.9 mg lactose.
Il-
linka użata gћall
-istampar fuq il-
kapsula fiha traċċi ta’ soja lecithin (0.48% tal
-
kompożizzjoni kollha tal
-linka
gћall
-istampar).
Għal
-
lista sħiħa ta' eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Kapsula iebsa li terћi l
-
mediċina bil
-mod.
Advagraf 0.5
mg kapsuli ibsin li jer
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-10-2023
Public Assessment Report Public Assessment Report Bulgarian 31-03-2008
Patient Information leaflet Patient Information leaflet Spanish 30-10-2023
Public Assessment Report Public Assessment Report Spanish 31-03-2008
Patient Information leaflet Patient Information leaflet Czech 30-10-2023
Public Assessment Report Public Assessment Report Czech 31-03-2008
Patient Information leaflet Patient Information leaflet Danish 30-10-2023
Public Assessment Report Public Assessment Report Danish 31-03-2008
Patient Information leaflet Patient Information leaflet German 30-10-2023
Public Assessment Report Public Assessment Report German 31-03-2008
Patient Information leaflet Patient Information leaflet Estonian 30-10-2023
Public Assessment Report Public Assessment Report Estonian 31-03-2008
Patient Information leaflet Patient Information leaflet Greek 30-10-2023
Public Assessment Report Public Assessment Report Greek 31-03-2008
Patient Information leaflet Patient Information leaflet English 30-10-2023
Public Assessment Report Public Assessment Report English 31-03-2008
Patient Information leaflet Patient Information leaflet French 30-10-2023
Public Assessment Report Public Assessment Report French 31-03-2008
Patient Information leaflet Patient Information leaflet Italian 30-10-2023
Public Assessment Report Public Assessment Report Italian 31-03-2008
Patient Information leaflet Patient Information leaflet Latvian 30-10-2023
Public Assessment Report Public Assessment Report Latvian 31-03-2008
Patient Information leaflet Patient Information leaflet Lithuanian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-10-2023
Public Assessment Report Public Assessment Report Lithuanian 31-03-2008
Patient Information leaflet Patient Information leaflet Hungarian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-10-2023
Public Assessment Report Public Assessment Report Hungarian 31-03-2008
Patient Information leaflet Patient Information leaflet Dutch 30-10-2023
Public Assessment Report Public Assessment Report Dutch 31-03-2008
Patient Information leaflet Patient Information leaflet Polish 30-10-2023
Public Assessment Report Public Assessment Report Polish 31-03-2008
Patient Information leaflet Patient Information leaflet Portuguese 30-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-10-2023
Public Assessment Report Public Assessment Report Portuguese 31-03-2008
Patient Information leaflet Patient Information leaflet Romanian 30-10-2023
Public Assessment Report Public Assessment Report Romanian 31-03-2008
Patient Information leaflet Patient Information leaflet Slovak 30-10-2023
Public Assessment Report Public Assessment Report Slovak 31-03-2008
Patient Information leaflet Patient Information leaflet Slovenian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-10-2023
Public Assessment Report Public Assessment Report Slovenian 31-03-2008
Patient Information leaflet Patient Information leaflet Finnish 30-10-2023
Public Assessment Report Public Assessment Report Finnish 31-03-2008
Patient Information leaflet Patient Information leaflet Swedish 30-10-2023
Public Assessment Report Public Assessment Report Swedish 31-03-2008
Patient Information leaflet Patient Information leaflet Norwegian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-10-2023
Patient Information leaflet Patient Information leaflet Croatian 30-10-2023

Search alerts related to this product

View documents history